What is HC Wainwright’s Forecast for MNPR FY2029 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of Monopar Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of $3.35 for the year, down from their previous estimate of $3.66. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

MNPR has been the subject of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Jones Trading reaffirmed a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Monopar Therapeutics Stock Up 15.3 %

Shares of MNPR stock opened at $38.53 on Wednesday. The company has a market capitalization of $235.11 million, a price-to-earnings ratio of -19.56 and a beta of 1.18. The firm has a fifty day moving average of $38.61 and a 200-day moving average of $24.63. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87).

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MNPR. JPMorgan Chase & Co. purchased a new stake in shares of Monopar Therapeutics during the fourth quarter valued at approximately $45,000. Geode Capital Management LLC lifted its holdings in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics in the fourth quarter valued at approximately $2,861,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics in the 4th quarter worth approximately $3,694,000. Finally, RA Capital Management L.P. bought a new stake in Monopar Therapeutics during the 4th quarter valued at $11,247,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.